RVNC
NASDAQ
$3.65
Revance Therapeutics Inc (RVNC)
Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company is headquartered in Newark, California.
Sector:
Healthcare
Industry:
Biotechnology
Target: $9.47 (+159.45%)
Market Cap
$380M
Revenue 5Y CAGR
+216.35%
Free Cash Flow Yield
-53.98%
Beta (5Y)
0.27
Price Chart
Valuation
Market Cap$380M
P/S1.48
P/B-2.33
Profitability
Total Revenue (TTM)$257M
Gross Profit (TTM)$104M
EBITDA-$190M
Profit Margin-63.6%
Operating Margin-53.9%
EPS-$1.96
Financial Health
Debt-to-Equity1477.8%
Free Cash Flow Yield-53.98%
Growth & Risk
Revenue 5Y CAGR+216.35%
Beta (5Y)0.27
Sharpe Ratio0.52